<DOC>
	<DOCNO>NCT00002020</DOCNO>
	<brief_summary>To evaluate safety tolerance , patient severe clinical manifestation HIV infection , zidovudine ( AZT ) administer daily 48 week low dose every 4 hour high dose every 12 hour .</brief_summary>
	<brief_title>Trial Alternative Dosing Regimen Oral Retrovir Patients With AIDS Advanced ARC</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis treatment Pneumocystis carinii pneumonia ( PCP ) consist either trimethoprim / sulfamethoxazole , aerosolized pentamidine , pyrimethamine / sulfadoxine , dapsone allow discretion investigator . Patients follow excluded : Any immediately lifethreatening infection medical condition present time study entry . Any active opportunistic infection require chronic therapy time study entry . Patients PCP may randomize study medication follow minimum 7day course therapy result stabilization disease . Patients stabilized disease must fever &lt; 39 C least 48 hour , pO2 ( room air ) = &gt; 60 mm , Arterial/alveolar gradient = &lt; 30 mm . Diagnosis AIDS Dementia Complex . Received 4 week antiretroviral therapy previously discontinue antiretroviral therapy due drug relate toxicity . Diseases condition list Exclusion Coexisting Conditions . Patients must follow : Seropositive HIV infection document federally license ELISA confirm Western blot . Advanced HIV disease AIDSrelated complex . Ability give inform consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : AIDS malignant disease likely require cytotoxic chemotherapy . Diagnosis AIDS Dementia Complex . Impaired renal function ( Creatinine clearance &lt; 50 ml/min/1.73m2 serum creatinine = &gt; 2 mg/dl ) . Impaired hepatic function ( ALT = &gt; 5 x upper limit normal ) . Fever &gt; 39 C entry . Concurrent Medication : Excluded : Any experimental therapy . Drugs cause significant bone marrow suppression . Cytolytic chemotherapy . Drugs cause significant nephrotoxicity hepatotoxicity . Concurrent Treatment : Excluded : Radiation therapy ( exception electron beam therapy area &lt; 100 cm2 ) . Prior Medication : Excluded within 2 week study entry : Any experimental therapy . Drugs cause significant bone marrow suppression . Cytolytic chemotherapy . Drugs cause significant nephrotoxicity hepatotoxicity . Excluded within 4 week entry : Immunomodulating agent , include pharmacological dos steroid 10 day ( except management severe PCP case duration exceed 21 day ) . Interferon . Isoprinosine . IL2 . Excluded within 8 week entry : Antiretroviral agent include : Ribavirin . Dideoxycytidine ( ddC ) . Dideoxyadenosine ( ddA ) . Didanosine ( ddI ) . Foscarnet . Dextran Sulfate . AL721 . Retrovir ( Zidovudine , AZT ) great 4 week within 90 day study entry , patient originally discontinue Retrovir due drugrelated toxicity . Drugs metabolize hepatic glucuronidation may alter metabolism Retrovir use chronically . Prior Treatment : Excluded : Radiation therapy ( exception electron beam therapy area &lt; 100 cm2 ) within 2 week study entry . Known active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1992</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>